|

Cognitive Screening in Lung Cancer Patients

RECRUITINGSponsored by European Institute of Oncology
Actively Recruiting
SponsorEuropean Institute of Oncology
Started2024-01-10
Est. completion2025-12-31
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06727370

Summary

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
* Age ≥ 18 years
* Patients able to speak and read the local language(s) fluently
* Acceptance and signature of informed consent

Exclusion Criteria:

* Age ≥ 70
* Presence of brain metastases
* Patients with concomitant neurological or psychiatric disorders.
* Patients undergoing brain radiotherapy
* Previous diagnosis of lung cancer

Conditions5

CancerLung CancerLung DiseaseNSCLC (Non-small Cell Lung Cancer)SCLC

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.